&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-05-22, 19:15

CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU
Bonita Conti

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-05-18, 13:00

JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment
Kristi Tafoya

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-12-20, 03:10

U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Lino McAdams

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-12-10, 17:35

JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China
Britney MacDevitt

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-10-22, 17:12

JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
Jillian Pearce

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-10-09, 17:05

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-29, 13:05

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-05-19, 23:15

Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-02-10, 20:05

Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Bud Eliott

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-16, 17:05

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Dora Legere

Popular Posts